Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-05-12 Purchase | 2022-05-16 08:33 am | Nuvectis Pharma Inc. | NVCT | Hoberman Kenneth Director | 6,000 | $17.4 | $104,400 | 55,140 (Direct) | View |
| 2020-03-09 Sale | 2020-03-13 9:31 pm | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 26,191 | $4.9716 | $130,211 | 771,764 (Direct) | View |
| 2020-02-25 Sale | 2020-02-28 9:31 pm | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 11,547 | $6.42 | $74,132 | 797,955 (Direct) | View |
| 2020-01-22 Sale | 2020-01-24 9:31 pm | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 22,139 | $7.02 | $155,416 | 601,085 (Direct) | View |
| 2020-01-08 Sale | 2020-01-10 9:16 pm | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 13,228 | $10.37 | $137,174 | 623,224 (Direct) | View |
| 2019-12-23 Sale | 2020-01-03 5:19 pm | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 46,312 | $10.84 | $501,959 | 636,452 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-19 Option Award | 2024-06-20 6:05 pm | N/A N/A | TG THERAPEUTICS INC. | TGTX | Hoberman Kenneth Director | 22,250 | $0 | 264,935 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-13 4:22 pm | N/A N/A | Nuvectis Pharma Inc. | NVCT | Hoberman Kenneth Director | 30,000 | $0 | 103,140 (Direct) | View |
| 2023-09-28 Option Award | 2023-09-29 5:01 pm | N/A N/A | TG THERAPEUTICS INC. | TGTX | Hoberman Kenneth Director | 20,000 | $0 | 242,685 (Direct) | View |
| 2023-06-16 Option Award | 2023-06-20 08:15 am | N/A N/A | Nuvectis Pharma Inc. | NVCT | Hoberman Kenneth Director | 18,000 | $0 | 73,140 (Direct) | View |
| 2022-07-20 Option Award | 2022-07-22 4:31 pm | N/A N/A | TG THERAPEUTICS INC. | TGTX | Hoberman Kenneth Director | 43,732 | $0 | 222,685 (Direct) | View |
| 2022-04-01 Option Award | 2022-04-05 4:47 pm | 2023-04-01 2032-04-01 | Nuvectis Pharma Inc. | NVCT | Hoberman Kenneth Director | 15,000 | $0 | 15,000 (Direct) | View |
Ownership | 2022-02-08 08:29 am | N/A N/A | Nuvectis Pharma Inc. | NVCT | Hoberman Kenneth Director | 0 | $0 | 78,390 (Direct) | View |
| 2021-06-18 Option Award | 2021-06-22 6:25 pm | N/A N/A | TG THERAPEUTICS INC. | TGTX | Hoberman Kenneth Director | 20,000 | $0 | 178,953 (Direct) | View |
| 2020-06-22 Option Award | 2020-06-24 7:50 pm | N/A N/A | TG THERAPEUTICS INC. | TGTX | Hoberman Kenneth Director | 15,000 | $0 | 158,953 (Direct) | View |
| 2020-06-10 Disposition | 2020-06-10 11:18 am | N/A 2026-01-07 | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 69,058 | $0 | 0 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-10 11:18 am | N/A N/A | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 600,000 | $0 | 0 (Direct) | View |
| 2020-06-10 Equity Swap | 2020-06-10 11:18 am | N/A N/A | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 1,374,352 | $0 | 0 (Direct) | View |
| 2020-02-10 Option Award | 2020-02-14 9:29 pm | N/A N/A | STEMLINE THERAPEUTICS INC | STML | Hoberman Kenneth Chief Operating Officer | 208,417 | $0 | 809,502 (Direct) | View |